Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Medical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society.Menopause N Y N. 2014; 21: 1063-1068
- The role of hormone therapy in urogenital health after menopause.Best Pract Res Clin Endocrinol Metab. 2021; 35: 101595
- Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.Am J Obstet Gynecol. 2016; 215: 704-711
- Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.Menopause N Y N. 2017; 24: 1246-1256
- Vaginal atrophy across the menopausal age: results from the ANGEL study.Climacteric J Int Menopause Soc. 2019; 22: 85-89
- Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.Menopause N Y N. 2018; 25: 1339-1353
- The role of local estrogen therapy in the management of pelvic floor disorders.Climacteric J Int Menopause Soc. 2016; 19: 162-171
- Estrogenic action on innate defense mechanisms in the urinary tract.Maturitas. 2014; 77: 32-36
- Preventing urinary tract infections after menopause without antibiotics.Maturitas. 2017; 99: 43-46
- Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy.Menopause N Y N. 2014; 21: 450-458
- The role of estrogens in female lower urinary tract dysfunction.Urology. 2003; 62: 45-51
- Recognizing and treating urogenital atrophy in postmenopausal women.J Womens Health. 2010; 19: 425-432
- Genitourinary syndrome of menopause: common problem, effective treatments.Cleve Clin J Med. 2018; 85: 390-398
- A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.Menopause N Y N. 2019; 26: 431-453
- Local oestrogen for pelvic floor disorders: a systematic review.PLoS One. 2015; 10: e0136265
- A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.N Engl J Med. 1993; 329: 753-756
- Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women.Menopause N Y N. 2012; 19: 630-635
- Local effects of vaginally administered estrogen therapy: a review.J Pelvic Med Surg. 2009; 15: 105-114
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.Lancet Lond Engl. 2019; 394: 1159-1168
- BMS - Consensus statement.Post Reprod Health. 2018; 24: 133-138
- Systemic or vaginal hormone therapy after early breast cancer: a danish observational cohort study.J Natl Cancer Inst. 2022; 20: djac112
- Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.Climacteric J Int Menopause Soc. 2022; 28: 1-7
- Mp30-15 prevalence of urinary tract infections in women with genitourinary syndrome of menopause and the impact of vaginal prasterone on urinary tract infections.J Urol. 2020; 203: e443-e444
- Prasterone in the treatment of mild to moderate urge incontinence: an observational study.Menopause N Y N. 2022; 29: 957-962
- The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.J Sex Med. 2014; 11: 487-497
- Pharmacologic evaluation of ospemifene.Expert Opin Drug Metab Toxicol. 2010; 6: 773-779
- Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?.Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2018; 34: 666-669
- Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study.Sex Med. 2018; 6: 154-161
- Vaginal rejuvenation using energy-based devices.Int J Womens Dermatol. 2016; 2: 85-88
- The effect of fractional CO2 laser treatment on the symptoms of pelvic floor dysfunctions: pelvic floor distress inventory-20 questionnaire.Lasers Surg Med. 2019; 51: 882-886
- Fractional CO2 laser of the vagina for genitourinary syndrome of menopause: Is the out-of-pocket cost worth the outcome of treatment?.Lasers Surg Med. 2017; 49: 882-885
- Current treatment options for postmenopausal vaginal atrophy.Int J Womens Health. 2018; 10: 387-395
- Testosterone and vaginal function.Sex Med Rev. 2020; 8: 379-392
- Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.Oncologist. 2011; 16: 424-431
- Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy.Sex Med. 2014; 2: 8-15
- Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) for healthy aging in women.Front Endocrinol. 2019; 10: 561
- The American Association of Clinical Anatomists (AACA): the other American anatomy association.Anat Rec. 1999; 257: 154-156
- A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women.Am J Obstet Gynecol. 1999; 180: 1072-1079
- Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.Climacteric J Int Menopause Soc. 2021; 24: 19-24
- Pelvic floor muscle training: mechanisms of action for the improvement of genitourinary syndrome of menopause.Climacteric J Int Menopause Soc. 2020; 23: 468-473
Article info
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
